IL-4, IL-13, IL-22, and IL-13 can reduce the protein expression of FLG and activate the release of bradykinin (141, 142), and the effectiveness of anti-IL-4 and anti-IL-13 in AD treatment shows the importance of the type 2 immune response in humans with AD (143). Here, IL13 is linked to Alzheimer disease.